secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2026-08-03T21:24:41+00:00
Accession:  0001493152-26-035864
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma spins out AI platform as Open-Medicine AI, signs commercial licenses
--------------------------------------------------------------------------------

- Lantern Pharma (LTRN) creates Open-Medicine AI as a separate company to commercialize its multi-agent AI co-scientist platform.
- Commercial licensing agreements executed between Lantern and OMAI for withZeta.ai-related models, data, and assets.
- Board approved; structure consistent with May 2026 registered direct financing led by Empery Asset Management.
- OMAI to expand beyond oncology into other disease areas; global AI drug discovery market projected >$10B by 2030.
- AI Center of Excellence in Bengaluru, India established in Q1 2026 to support platform scaling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226035864/0001493152-26-035864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226035864/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer